DDrare: Database of Drug Development for Rare Diseases

Searched query = "Single Ventricle", "SV", "Single ventricle heart defect", "Univentricular heart", "UVH", "Single ventricular circulation syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACETYLSALICYLIC ACID; ACT-064992; Acetylsalicylic acid; Administration of an ACE-inhibitor or not; Aesculus Hippocastanum / Horse Chestnut; Ambrisentan; Arginine; Aspirin; Autologous Tissue-Engineered Vascular Graft; BAY 59-7939; Bosentan; Carvedilol; Colchicine; Digoxin; Enalapril; Eplerenone; Horse chestnut; JNJ-39039039; Liothyronine; Liothyronine I 131; MACITENTAN; MPC; MZ101; Macitentan; Milk; Mysildecard; Mysildecard 20 mg; Nitric Oxide; Normal Saline; ODSH at 0.125 mg/kg/h; ODSH at 0.250 mg/kg/h; ODSH at 0.375 mg/kg/h; Opsumit; Opsumit®; Other: Human Milk Derived Fortifier; Other: Human/Bovine Milk; RIVAROXABAN; Rexlemestrocel-L; Rivaroxaban; SCRM001_TEVG; Sildenafil; Sildenafil by injection; Spironolactone; Spironolactone (drug); Sugar pill; Tadalafil; Tadalafil Citrate; Tracleer; Treprostinil; Udenafil; Vasopressin; Vasopressin, Arginine; Vitamin C; Xarelto

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02080637 (ClinicalTrials.gov)	July 2015	21/2/2014	Ambrisentan in Single Ventricle	Safety, Pharmacokinetics (PK) and Hemodynamic Effects of Ambrisentan in Single Ventricle Pediatric Patients	Hypoplastic Left Heart Syndrome;Hypoplastic Right-sided Heart Complex	Drug: Ambrisentan;Other: Placebo	Kevin Hill	NULL	Completed	24 Months	120 Months	All	16	Phase 2	United States
2	NCT01971580 (ClinicalTrials.gov)	August 2012	23/10/2013	The Effects of Ambrisentan on Exercise Capacity in Fontan Patients	The Effects of Ambrisentan on Exercise Capacity in Fontan Patients	Single Ventricle Fontan Palliation	Drug: Ambrisentan	Washington University School of Medicine	NULL	Completed	18 Years	50 Years	All	28	Phase 4	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02080637
(ClinicalTrials.gov)

July 2015

21/2/2014

Ambrisentan in Single Ventricle

Safety, Pharmacokinetics (PK) and Hemodynamic Effects of Ambrisentan in Single Ventricle Pediatric Patients

Hypoplastic Left Heart Syndrome;Hypoplastic Right-sided Heart Complex

Drug: Ambrisentan;Other: Placebo

Kevin Hill

NULL

Completed

24 Months

120 Months

All

Phase 2

United States

NCT01971580
(ClinicalTrials.gov)

August 2012

23/10/2013

The Effects of Ambrisentan on Exercise Capacity in Fontan Patients

Single Ventricle Fontan Palliation

Drug: Ambrisentan

Washington University School of Medicine

NULL

Completed

18 Years

50 Years

All

Phase 4

United States